Key Challenges and Opportunities Associated with the Use of In Vitro Models to Detect Human DILI: Integrated Risk Assessment and Mitigation Plans

Figure 2

The schema to refine the drug labeling based DILI annotations by weighting the causality evidence. Three verified categories (Most-, Less-, and No-DILI-concern) and one “Ambiguous DILI-concern” group were classified in the new schema. For more details, please refer to Chen et al. [65]. Figure reproduced with permission.